15 Jul 2026

CRC Research Update — July 15, 2026

Creator: The CRC Digest
Published: 2026-07-15T20:36:21Z

Today's colorectal cancer research highlights

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

Signal Key

TRIAL DATA clinical trial results, efficacy data, survival endpoints TREATMENT new treatment options, regimen changes, combination therapies REGULATORY FDA/EMA approvals, guideline updates, NCCN/ESMO changes RESEARCH cancer biology, biomarker discoveries, resistance pathways SCREENING screening, colonoscopy guidelines, liquid biopsy, molecular profiling LIVING WITH CRC survivorship, quality of life, side effects, patient decision-making, caregiver support

European Commission Approves Cetuximab Plus Encorafenib and FOLFOX for BRAF V600E Metastatic CRC
The European Commission has approved Erbitux (cetuximab) in combination with encorafenib and FOLFOX chemotherapy as a first-line treatment for metastatic colorectal cancer with BRAF V600E mutation. This approval provides a new targeted treatment option for patients with this specific genetic subtype. (albawaba.com)
Multi-Locus Blood Test Shows Promise for Early CRC Detection
A prospective study enrolled 35 patients with colorectal cancer undergoing surgery and 57 healthy controls undergoing screening colonoscopy at Asan Medical Center in Seoul between July 2024 and January 2025. A multi-locus circulating tumor DNA methylation assay showed diagnostic potential for colorectal cancer detection. (Int J Mol Sci)
Polygenic Risk Scores May Help Personalize CRC Screening
Analysis of 112,204 individuals from the Copenhagen Hospital Biobank found that polygenic risk scores stratified lifetime adenoma and CRC risk independently of ancestry and sex, suggesting potential for risk-based screening strategies. (Br J Cancer)
Phone-Based Patient Navigation Tested to Improve Genetic Testing Access
A pilot randomized trial in an academic health system evaluated whether offering newly diagnosed CRC patients free, phone-based patient navigation increased rates of referral, counseling, and germline genetic testing compared to usual care. The study aimed to address barriers to genetic counseling attendance. (Genet Med)

🧬 Biomarker Spotlight

Research by genetic subtype — KRAS, BRAF, MSI-H, HER2, and more

KRAS Exon 2 vs Non-Exon 2 Mutations Show Different Clinical Profiles
A retrospective study of 272 patients with microsatellite stable metastatic CRC compared clinical and inflammatory profiles between KRAS exon 2 mutations (236 patients) and less common non-exon 2 mutations. (Cancers)
KRAS Mutations Promote Immune Suppression Through DNA Clearance
Preclinical research found that oncogenic KRAS promotes extracellular DNA clearance, which may drive immunosuppression in colorectal cancer and affect the tumor microenvironment. (Cancer Res)

⚥ Sex & Gender in CRC

Research on sex-specific differences in treatment, outcomes, and screening

Cancer Cachexia and Chemotherapy Show Sex-Specific Differences in Mice
A preclinical study using male and female mice with Colon-26 tumors found biological sex differences in cancer cachexia progression during chemotherapy with 5-fluorouracil, cisplatin, or paclitaxel. (Am J Physiol Endocrinol Metab)

Research continues to advance personalized approaches to CRC screening, treatment, and supportive care.

Subscribe to The CRC Digest